| Year |
Citation |
Score |
| 2023 |
Barone A, De Simone G, Ciccarelli M, Buonaguro EF, Tomasetti C, Eramo A, Vellucci L, de Bartolomeis A. A Postsynaptic Density Immediate Early Gene-Based Connectome Analysis of Acute NMDAR Blockade and Reversal Effect of Antipsychotic Administration. International Journal of Molecular Sciences. 24. PMID 36901803 DOI: 10.3390/ijms24054372 |
0.581 |
|
| 2020 |
Iasevoli F, Buonaguro EF, Avagliano C, Barone A, Eramo A, Vellucci L, de Bartolomeis A. The Effects of Antipsychotics on the Synaptic Plasticity Gene Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. International Journal of Molecular Sciences. 21. PMID 32756473 DOI: 10.3390/Ijms21155555 |
0.757 |
|
| 2020 |
van Erp TG, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG. Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study. Psychiatry Research. Neuroimaging. 301: 111085. PMID 32450497 DOI: 10.1016/J.Pscychresns.2020.111085 |
0.365 |
|
| 2018 |
Correll CU, Shi L, Weiss C, Hobart M, Eramo A, Duffy RA, Weiller E, Baker RA. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. Cns Spectrums. 1-11. PMID 30306884 DOI: 10.1017/S1092852918001086 |
0.383 |
|
| 2017 |
Salzman PM, Raoufinia A, Legacy S, Such P, Eramo A. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatric Disease and Treatment. 13: 1125-1129. PMID 28461748 DOI: 10.2147/Ndt.S133433 |
0.382 |
|
| 2017 |
Naber D, Baker RA, Eramo A, Forray C, Hansen K, Sapin C, Peters-Strickland T, Nylander AG, Hertel P, Nitschky Schmidt S, Loze JY, Potkin SG. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia Research. PMID 28433498 DOI: 10.1016/J.Schres.2017.04.013 |
0.393 |
|
| 2017 |
Ismail Z, Peters-Strickland T, Miguelez M, Baker RA, Hertel P, Eramo A, Jin N, Perry P, Sanchez R, McQuade RD, Kane JM. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores. Journal of Clinical Psychopharmacology. PMID 28383362 DOI: 10.1097/Jcp.0000000000000710 |
0.407 |
|
| 2017 |
Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Frontiers in Psychiatry. 8: 42. PMID 28367128 DOI: 10.3389/Fpsyt.2017.00042 |
0.379 |
|
| 2017 |
Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander AG, Hertel P, Steen Andersen H, Eramo A, Hansen K, Naber D. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. International Clinical Psychopharmacology. PMID 28252452 DOI: 10.1097/Yic.0000000000000168 |
0.336 |
|
| 2017 |
Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, Tomasetti C, de Bartolomeis A. Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28235555 DOI: 10.1016/J.Pnpbp.2017.02.012 |
0.76 |
|
| 2017 |
Raoufinia A, Peters-Strickland T, Nylander AG, Baker RA, Eramo A, Jin N, Bricmont P, Repella J, McQuade RD, Hertel P, Larsen F. Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. The International Journal of Neuropsychopharmacology. PMID 28204607 DOI: 10.1093/Ijnp/Pyw116 |
0.361 |
|
| 2016 |
Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander AG, Hertel P, Nitschky Schmidt S, Eramo A, Hansen K, Naber D. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The International Journal of Neuropsychopharmacology. PMID 27927736 DOI: 10.1093/Ijnp/Pyw093 |
0.371 |
|
| 2016 |
Sapin C, Hartry A, Kamat SA, Beillat M, Baker RA, Eramo A. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context. 5: 212301. PMID 27708677 DOI: 10.7573/Dic.212301 |
0.34 |
|
| 2016 |
Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, Johnson BR, Sanchez R. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. Cns Spectrums. 1-6. PMID 27531181 DOI: 10.1017/S1092852916000365 |
0.396 |
|
| 2016 |
Wilson M, Gutierrez B, Offord SJ, Blanchette CM, Eramo A, Earnshaw S, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5: 212273. PMID 27114739 DOI: 10.7573/Dic.212273 |
0.354 |
|
| 2016 |
Karson C, Duffy RA, Eramo A, Nylander AG, Offord SJ. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment. 12: 57-67. PMID 26792993 DOI: 10.2147/Ndt.S96392 |
0.394 |
|
| 2016 |
Potkin S, Schmidt SN, Salzman P, Such P, Ettrup A, Eramo A, Hansen K, Naber D. Effect sizes of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia: a post-hoc analysis of QUALIFY European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31618-2 |
0.401 |
|
| 2016 |
Salzman P, Schmidt SN, Eramo A, Hansen K, Ettrup A, Such P. Effects of aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by disease severity: a post-hoc analysis of QUALIFY European Neuropsychopharmacology. 26: S555-S556. DOI: 10.1016/S0924-977X(16)31603-0 |
0.381 |
|
| 2015 |
Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment. 11: 3095-104. PMID 26719694 DOI: 10.2147/Ndt.S91917 |
0.387 |
|
| 2015 |
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 168: 498-504. PMID 26232241 DOI: 10.1016/J.Schres.2015.07.007 |
0.358 |
|
| 2015 |
Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context. 4. PMID 25834621 DOI: 10.7573/Dic.212267 |
0.364 |
|
| 2015 |
Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, Johnson BR, Tsai LF, Carson WH, McQuade RD, Fleischhacker WW. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9: 79-87. PMID 25711509 DOI: 10.3371/Csrp.Kasa.022015 |
0.39 |
|
| 2015 |
de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, Avvisati L, Latte G, Tomasetti C. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 566-82. PMID 25649681 DOI: 10.1016/J.Euroneuro.2015.01.003 |
0.762 |
|
| 2015 |
Raoufinia A, Baker RA, Eramo A, Nylander AG, Landsberg W, Kostic D, Larsen F. Initiation of aripiprazole once-monthly in patients with schizophrenia. Current Medical Research and Opinion. 31: 583-92. PMID 25586294 DOI: 10.1185/03007995.2015.1006356 |
0.403 |
|
| 2015 |
Kane JM, Zhao C, Johnson BR, Baker RA, Eramo A, McQuade RD, Duca AR, Sanchez R, Peters-Strickland T. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics. 18: 145-54. PMID 25347448 DOI: 10.3111/13696998.2014.979936 |
0.328 |
|
| 2015 |
Potkin SG, Loze J, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander A, Hertel P, Andersen HS, Eramo A, Hansen K, Naber D. P.3.d.084 Aripiprazole once-monthly is superior to paliperidone palmitate: results from QUALIFY, a randomized, head-to-head clinical study in schizophrenia European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30731-8 |
0.381 |
|
| 2015 |
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander A, Hertel P, Andersen HS, Eramo A, Loze J, Potkin S. P.3.d.080 Aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by age: Results from QUALIFY, a head-to-head study European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30728-8 |
0.369 |
|
| 2015 |
Potkin SG, Loze J, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander A, Hertel P, Andersen HS, Eramo A, Hansen K, Naber D. P.3.d.078 Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: Results from QUALIFY, a head-to-head study in schizophrenia European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30726-4 |
0.363 |
|
| 2015 |
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander A, Hertel P, Andersen HS, Eramo A, Loze J, Potkin S. P.3.d.077 Clinical Global Impression after aripiprazole once-monthly and paliperidone palmitate: Results from QUALIFY, a head-to-head study in schizophrenia European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30725-2 |
0.376 |
|
| 2015 |
Peters-Strickland T, Raoufinia A, Nylander A, Baker RA, Eramo A, Jin N, McQuade RD, Hertel P, Larsen F. P.3.d.056 Deltoid injection of aripiprazole once-monthly in the treatment of schizophrenia European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30704-5 |
0.405 |
|
| 2015 |
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin S. Aripiprazole Once-monthly is Superior to Paliperidone Palmitate in a Randomized, Head-to-head Clinical Study European Psychiatry. 30: 923. DOI: 10.1016/S0924-9338(15)30721-5 |
0.35 |
|
| 2014 |
Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, Sanchez R. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 75: 1254-60. PMID 25188501 DOI: 10.4088/Jcp.14M09168 |
0.421 |
|
| 2014 |
Iasevoli F, Buonaguro EF, Sarappa C, Marmo F, Latte G, Rossi R, Eramo A, Tomasetti C, de Bartolomeis A. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 299-314. PMID 25025505 DOI: 10.1016/J.Pnpbp.2014.07.003 |
0.754 |
|
| 2014 |
Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British Journal of Psychiatry : the Journal of Mental Science. 205: 135-44. PMID 24925984 DOI: 10.1192/Bjp.Bp.113.134213 |
0.412 |
|
| 2014 |
Potkin SG, Bera R, Eramo A, Lau G. A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses. 1-35. PMID 24846880 DOI: 10.3371/Csrp.Pori.050614 |
0.321 |
|
| 2014 |
Citrome L, Kamat SA, Sapin C, Baker RA, Eramo A, Ortendahl J, Gutierrez B, Hansen K, Bentley TG. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics. 17: 567-76. PMID 24758296 DOI: 10.3111/13696998.2014.917089 |
0.379 |
|
| 2014 |
Eramo A, Baker RA, Nylander AG, Tsai LF, Peters-Strickland T, Sanchez R. P.3.d.040 Previous oral aripiprazole dose (10 or 30 mg/day): effect on the efficacy and tolerability of aripiprazole once-monthly European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70873-9 |
0.339 |
|
| 2014 |
Kane JM, Zhao C, Johnson B, Baker RA, Eramo A, McQuade R, Duca A, Sanchez R, Peters-Strickland T. P.3.d.037 Effects of aripiprazole once-monthly in patients with schizophrenia switched from oral antipsychotics to aripiprazole once-monthly European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70870-3 |
0.406 |
|
| 2014 |
Peters-Strickland T, Baker RA, McQuade R, Jin N, Eramo A, Perry P, Johnson B, Duca A, Sanchez R. P.3.d.035 Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70868-5 |
0.382 |
|
| 2014 |
Kane JM, Zhao C, Johnson B, Baker RA, Eramo A, McQuade RD, Duca A, Sanchez R, Peters-Strickland T. P.3.d.034 Effects of aripiprazole once-monthly on functioning in patients with schizophrenia European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70867-3 |
0.391 |
|
| 2014 |
Baker RA, Eramo A, Tsai LF, Peters-Strickland T, Sanchez R. P.3.d.033 The effects of aripiprazole once-monthly on the PANSS Marder factors in the treatment of patients with schizophrenia European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70866-1 |
0.406 |
|
| 2014 |
Hert MD, Eramo A, Landsberg W, Tsai LF, Kostic D, Baker R. EPA-0809 - Aripiprazole once-monthly for the treatment of schizophrenia in obese and non-obese patients; a post-hoc analysis European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78151-9 |
0.316 |
|
| 2014 |
Baker R, Fleischhacker WW, Sanchez R, Tsai LF, Peters-Strickland T, Eramo A, Kostic D, Kane J. EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78135-0 |
0.372 |
|
| 2014 |
Baker RA, Eramo A, Nylander A, Tsai L, Peters-Strickland TS, Kostic D, Sanchez R. Poster #T13 THE EFFECT OF PREVIOUS DOSE OR ORAL ARIPIPRAZOLE (10 OR 30 MG/DAY) ON THE EFFICACY AND TOLERABILITY OF ARIPIPRAZOLE ONCE-MONTHLY: RESULTS FROM POST-HOC ANALYSES FROM TWO DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70830-8 |
0.306 |
|
| 2014 |
Eramo A, Fleischhacker WW, Sanchez R, Tsai L, Peters-Strickland TS, Baker RA, Kostic D, Kane JM. Poster #S233 ALL-CAUSE DISCONTINUATION AND SAFETY OF ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA: A POOLED ANALYSIS OF TWO DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIALS Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70512-2 |
0.367 |
|
| 2014 |
Kamat S, Blanchette C, Wilson M, Tangirala M, Earnshaw S, Offord S, Gutierrez B, Eramo A, Baker R. Health care cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.1262 |
0.331 |
|
| 2013 |
Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Baker RA, Eramo A, Sanchez R, McQuade R. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Current Medical Research and Opinion. 29: 1241-51. PMID 23822566 DOI: 10.1185/03007995.2013.821973 |
0.398 |
|
| 2013 |
de Bartolomeis A, Sarappa C, Buonaguro EF, Marmo F, Eramo A, Tomasetti C, Iasevoli F. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 46: 1-12. PMID 23800465 DOI: 10.1016/J.Pnpbp.2013.06.010 |
0.766 |
|
| 2013 |
Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics. 16: 917-25. PMID 23663091 DOI: 10.3111/13696998.2013.804411 |
0.326 |
|
| 2013 |
Kane J, Zhao J, Baker RA, Eramo A, McQuade RD, Sanchez R, Peters-Strickland T. P.3.d.037 Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for schizophrenia European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70760-0 |
0.372 |
|
| 2013 |
Fleischhacker WW, Sanchez R, Jin N, Peters-Strickland T, Johnson BR, Eramo A, Loze JY, McQuade RD, Carson WH, Kane J. P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70751-X |
0.359 |
|
| 2013 |
Buonaguro E, Marmo F, Sarappa C, Eramo A, Tomasetti C, Iasevoli F, De Bartolomeis A. P.1.g.054 Gene-expression imaging by N-methyl-D-aspartate receptor antagonists: implications for dopamine–glutamate interplay in psychosis European Neuropsychopharmacology. 23: S220-S221. DOI: 10.1016/S0924-977X(13)70341-9 |
0.766 |
|
| 2013 |
Potkin S, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Jin N, Baker RA, Eramo A, Sanchez R, McQuade RD. 2283 – Safety and tolerability of aripiprazole once-monthly initiated in adults with schizophrenia stabilized on atypical oral antipsychotics other than aripiprazole European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77143-8 |
0.362 |
|
| 2013 |
Eramo A, Fleischhacker WW, Sanchez R, Perry P, Jin N, Johnson B, McQuade RD, Carson WH, Kane J. 2277 – A placebo-controlled study of efficacy and safety of aripiprazole once-monthly for long-term maintenance treatment in schizophrenia European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77138-4 |
0.331 |
|
| 2013 |
Avvisati L, Rossi R, Latte G, Buonaguro EF, Eramo A, Marmo F, Tomasetti C, Sarappa C, Iasevoli F, Bartolomeis Ad. 2251 – Cortical and subcortical gene-expression imaging by different n-methyl-daspartate receptor (nmda-r) antagonists at glutammatergic synapses: implications for dopamine-glutamate interplay in psychoses European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77115-3 |
0.792 |
|
| 2013 |
Fleischhacker WW, Perry P, Sanchez R, Jin N, Peters-Strickland T, Johnson B, Baker R, Eramo A, McQuade RD, Carson WH, Kane JM. Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia Value in Health. 16. DOI: 10.1016/J.Jval.2013.08.1419 |
0.375 |
|
| 2013 |
Kamat S, Gutierrez B, Eramo A, Zubek D, Baker RA, Lin J, Karson C. Initial assessment of real-world usage of extended-release injectable paliperidone palmitate among medicaid insured schizophrenia patients Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.1580 |
0.367 |
|
| 2012 |
Iasevoli F, Sarappa C, Eramo A, Bonaguro EF, Marmo F, Bartolomeis A. Poster #9 ANTAGONISTS AT N-METHYL-D-ASPARTATE RECEPTOR (NMDA-R) WITH DIFFERENT CLINICAL PROFILE AFFECT DIFFERENTLY THE TRANSCRIPTS OF CONSTITUTIVE AND INDUCIBLE EARLY GENES AT POSTSYNAPTIC DENSITY Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70581-9 |
0.757 |
|
| 2011 |
Gardoni F, Zianni E, Eramo A, Canonico PL, Di Luca M. Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. European Journal of Pharmacology. 670: 458-63. PMID 21946113 DOI: 10.1016/J.Ejphar.2011.09.028 |
0.462 |
|
| 2003 |
Eramo A, Fiore G, Gentile S, Pellegrino F, Muscettola G, de Bartolomeis A. The forgotten therapy: Depot neuroleptics in the era of atypical antipsychotics, a community based study Schizophrenia Research. 60: 38. DOI: 10.1016/S0920-9964(03)80111-1 |
0.683 |
|
| Show low-probability matches. |